106-120 of 137
Is Managing Gout in the Nephrology Clinic a Challenge?
MinuteCE®Is Managing Gout in the Nephrology Clinic a Challenge?
Richard Johnson, MD
Abdul Abdellatif, MD, FASN
Center of the Target: Which Patients Are Most Likely to Develop Gout?
MinuteCE®Center of the Target: Which Patients Are Most Likely to Develop Gout?
Richard Johnson, MD
Abdul Abdellatif, MD, FASN
Treat or Refer: Who Is Responsible for Managing Gout?
MinuteCE®Treat or Refer: Who Is Responsible for Managing Gout?
John K. Botson, MD, RPh
Abdul Abdellatif, MD, FASN
Can You Manage Patients With Uncontrolled Gout More Effectively?
MinuteCE®Can You Manage Patients With Uncontrolled Gout More Effectively?
Abdul Abdellatif, MD, FASN
John K. Botson, MD, RPh
Abdul Abdellatif, MD, FASN
Richard Johnson, MD
What’s New About Gout? Rheumatology Perspective
MinuteCE®What’s New About Gout? Rheumatology Perspective
Richard Johnson, MD
John K. Botson, MD, RPh
- advertisement
What Are the Emerging Therapies for Managing Gout?
MinuteCE®What Are the Emerging Therapies for Managing Gout?
Richard Johnson, MD
John K. Botson, MD, RPh
Should We Look for Gout in the Cardiology Clinic?
MinuteCE®Should We Look for Gout in the Cardiology Clinic?
Richard Johnson, MD
Brittany Weber, MD, PhD
A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases
CME/CEA Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases
Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Patrick Rossignol, MD, PhD
Siân Griffin, MD, PhD
Jürgen Floege, MD
Loreto Gesualdo, MD, FERA
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
CME/CEDirected Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Lucio Manenti, MD, PhD
Jonathan Barratt, MD, PhD
Annette Bruchfeld, MD, PhD
- advertisement
KALMing the Itch: Improving QoL in Patients with CKD-aP
CME/CEKALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
CME/CEUnderstanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Jonathan Barratt, MD, PhD
Donald E. Kohan, MD, PhD
Separating Fact from Fiction: The Realities of CKD-aP
CME/CESeparating Fact from Fiction: The Realities of CKD-aP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD
